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Abstract
Aim: To assess serum Hepatocyte Growth Factor (HGF) levels in individuals with depression and to test the hypothesis that there is a 
relationship between severity of depression and HGF concentration.
Subjects and methods: Serum from 26 clinically depressed individuals and 19 controls were tested for serum HGF using ELISAs. 
Correlation was established between HGF concentration and disease severity.
Results: Depressed individuals had significantly lower serum levels of HGF compared to controls (P , 0.0001). HGF concentration 
correlated with overall depressive behavior (P = 0.03) and specifically depression (P = 0.02), but not anxiety (P = 0.36).
Discussion: These results suggest an association between HGF serum levels and clinically depressed individuals and demonstrate 
a correlation between severity of depression and HGF levels. Further studies of the predictive strength of HGF as a biomarker for 
depression may be warranted.
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Clinical depression is a considerable public health 
problem.1 Approximately 32 to 35 million adults in 
the  United  States  have  experienced  depression  at 
some point in their life and approximately 13   million 
adults have experienced depression within the past 
year.2  Clinical  depression  is  also  a  considerable 
  medical  problem  as  those  with  major  depressive 
disorder  (MDD)  are  at  increased  risk  for  serious 
medical   illness, including cardiovascular disease,3–5 
diabetes,6–8 cancer,9–11 and stroke.12
Hepatocyte growth factor (HGF), an 82 kDa, 674 
amino acid residue heterodimeric   glycoprotein, was 
originally isolated from rat platelets.13,14 This growth 
factor has also been called scatter factor,   hepatopoietin 
A, and mammary growth factor.15 It is one of a small 
family  of  factors  lacking  significant    homology 
with other known growth factors, but including an 
  HGF-like factor known as macrophage   stimulating 
protein (MSP)16–19 HGF has mitogenic,   morphogenic, 
and  motogenic  effects  on  hepatocytes,  as  well  as 
endothelial,  mesenchymal  and    hematopoietic  cell 
types,18,20,21  and  demonstrates  noticeable  species 
cross-reactivity.22
HGF  regulates  cell  growth,  cell  motility,  and 
  morphogenesis  by  activating  a  tyrosine  kinase 
  signaling  cascade  after  binding  to  the  proto-
  oncogenic  c-Met  receptor  (translated  by  the  MET 
gene). HGF is secreted by mesenchymal cells and, 
although it was first considered to exert biological 
effects only on specific target cells, it has since been 
demonstrated to mediate inflammatory responses to 
tissue injury, and regulate cell growth, cell motil-
ity, and   morphogenesis in a wide variety of cells. Its 
ability  to  stimulate    branching  morphogenesis,  cell 
migration, survival and proliferation gives it a cen-
tral role in   angiogenesis, tissue regeneration, as well 
as tumorogenesis.23–29
Signaling by HGF has also been found to have 
anti-inflammatory, antifibrotic, and pro-regenerative 
activity on various types of tissue. But it seems to be 
particularly active in the nervous system, where it has 
been found to have neurotrophic and angiogenetic 
activity on CNS neurons, promote both the survival 
of neurons and the regeneration of injured nerves, and 
function as a target-derived axonal   chemoattractant, 
guiding axons to their target. As a result, it plays 
  significant roles in the development of the CNS.30
Because of the potential association between HGF 
and neurological disease we tested patient with clini-
cal depression for serum concentration of HGF and 
then compared those levels with severity of disease.
Materials and Methods
eLISA to measure serum HgF (eLISA 
kit, R&D Systems, Minneapolis, Minn.)
All  reagents  and  specimens  were  equilibrated  to 
room temperature before the assay was performed. 
A 1:51 dilution of the patient samples was   prepared 
by   mixing 10 µl of the patient’s sera with 0.5 ml of 
Serum Diluent. One hundred microliters of   calibrators 
(20–200 Eu/ml antibodies), positive and Negative con-
trol serums, serum diluent alone, and diluted patient 
samples were added to the   appropriate   microwells of a 
microculture plate (each well contained affinity puri-
fied polyclonal IgG to HGF). Wells were incubated 
for 60 minutes (±5 min) at room temperature, then 
washed 4x with wash buffer. One hundred microliters 
of pre-diluter anti-human IgG conjugated with HRP 
was added to all microwells, incubated for 30 min-
utes (±5 min) at room temperature, then wash 4x with 
wash buffer. One hundred microliters of enzyme sub-
strate was added to each microwell. After approxi-
mately 30 minutes at room temperature, the reaction 
was stopped by adding 50 µl of 1M sulfuric acid, then 
the wells were read at 405 nm with an ELISA reader 
(BioRad Laboratories, Inc., Hercules, CA, USA).
subjects
experimental and controls
Serum  from  individuals  with  diagnosed  clinical 
depression (n = 26; 12 male; mean age 36.7 years) 
and controls (n = 18; 5 male; mean age 42.3 years) 
was obtained from patients presenting at the Health 
Research Institute/Pfeiffer Treatment Center. Most of 
these individuals were diagnosed using The Hamilton 
Rating  Scale  for  Depression  before  presenting 
for  treatment  at  the  Pfeiffer  Treatment  Center, 
Warrenville, Il.*
Patient  consent  was  obtained  from  all  patients 
involved in this study and this study was approved 
by the IRB of the Health Research Institute/Pfeiffer 
Treatment Center.
* The Pfeiffer Treatment Center is a   comprehensive treatment and research center, 
specializing in the care of with neurological disorders, including Depression.
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A modified Hamilton Scale was used to determine 
the severity of depression. Patients were asked to 
rate their depressive behavior such as;   irritability 
and  anger,  lack  of  ability  to  focus/concentrate, 
  racing  thoughts,  trouble  sleeping,  light  sensitiv-
ity, migraines, OCD behavior, intrusive thoughts, 
  overall    anxiety,    disorganization,  panic,  obsessive 
  behavior, and   overall depression. The patients were 
rated on a scale of 0–5 (5 being the highest) for each 
of these   behaviors. We evaluated the overall severity 
of depressive   behavior by establishing the mean of 
all of the scores for each patient and also compared 
the  overall  anxiety  and  overall  depression  rating 
of each patient. The overall severity of depressive 
behavior assessment includes assessment of all the 
behaviors (above). The overall anxiety and overall 
depression rating includes assessment of just anxi-
ety and   depression behavior, respectively.
serum/plasma
All experimental and control serums were treated in 
an  identical  fashion—frozen  at  −70C  immediately 
after collection and cell/serum separation, then stored 
at −70C until thawed for use in ELISAs.
statistics
Inferential statistics were derived from t-test with 95% 
confidence intervals. ANOVA analysis was used to 
do an analysis of variance and multiple   comparisons. 
Pearson Product Moment Correlation and Spearman’s 
Rank Correlation were used for correlation between 
HGF and severity of disease.
Results
Serum from 26 clinically depressed individuals and 
19 controls were tested for serum HGF using   ELISAs 
(described above). Each assay was repeated two or 
more times, with multiple wells for each serum in 
each assay.
Serum HGF concentration (pg/ml) of individuals 
with  clinical  depression  (N  =  26;  Mean  SD; 
HGF = 380.9 ± 96) were significantly lower than healthy 
controls (N = 19; Mean SD; HGF = 573.9 ± 142.8)   
(P 0.0001) (Table 1).
HGF concentration of individuals with depression 
was  compared  to  HGF  concentration.  There  was 
a  significant  positive  correlation  between  HGF 
concentration  and  severity  of  overall  depressive 
behavior  (Pearson  correlation  0.48;  Spearman’s 
correlation 0.37) (P = 0.03) (Fig. 1) and specific sever-
ity of depression (Pearson correlation 0.54; Spearman’s 
correlation 0.49) (P = 0.02) (Fig. 2), but not severity of 
anxiety (Pearson correlation −0.12; Spearman’s corre-
lation 0.08) (P = 0.36) (Fig. 3).
Discussion
HGF has been found to be associated with a variety of 
diseases  of  the  CNS.  For  instance,  immunohistochemistry 
using anti-HGF antibody has revealed more intense 
immunolabeling in Alzheimer’s disease (AD) than in 
control brains, and there appears to be a significant 
correlation between CSF HGF levels and white mat-
ter high-signal foci determined on brain magnetic reso-
nance imaging (MRI) in AD patients.31 In Amyotrophic 
lateral sclerosis (ALS), overexpression of hepatocyte 
growth factor (HGF) in the nervous system attenuates 
motoneuron death and axonal degeneration and pro-
longs the life span of transgenic mice overexpressing 
mutated Cu2+/Zn2+ superoxide dismutase.32 However, 
overexpression of HGF after gene transfer prevented 
neuronal death in a Parkinson’s Disease rat model.33 
Decreased levels of HGF has been found in autistic 
children with GI disease.40
Major depressive disorder has been found to be 
associated with oxidative stress34 and oxidative stress 
levels have been found to correlate with severity of 
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Figure 1. This scatter plot demonstrates a direct relationship between 
HgF concentration and Overall Severity of Depression (Mean value of 
depression behaviors) (P = 0.03).
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of GABA in mood disorders, particularly anxiety and 
depression.36
HGF expression has also been found to be   associated 
with  oxidative  stress  markers38  and    receptor  gene 
expression may be suppressed by   oxidative stress.37 
HGF has also been found to be   associated with GABA 
regulation,  particularly  through    anxiolytic    activity, 
modulating  GABAergic  inhibition  and    seizure 
susceptibility.39
This study reports an inversion relationship between 
serum Hepatocyte Growth Factor (HGF) concentration 
and severity of depressive symptoms among patients 
in treatment. Kahl et al41 measured angiogenic factors 
in patients with major   depressive disorder, comorbid 
with borderline personality   disorder, and did not note 
a statistically significant relationship between HGF and 
clinically-established  depression.  Also,  Wakatsuki42 
administered antisense DNA for hepatocyte growth fac-
tor to rats, causing a depressive and anxiogenic response. 
Our results, therefore, represent a novel finding.
Our study shows that depressed individuals have 
significantly lower levels of HGF than normal controls, 
and that there is a direct correlation between levels of 
HGF and severity of depression. We   suggest that the 
low levels of HGF may cause lower GABA, having 
an anxiogenic effect. This may also help to explain the 
significant number of depressed   individuals who also 
present with anxiety. To evaluate this relationship, future 
studies will assess more patients with depression and 
evaluate GABA levels along with HGF concentration.
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HGF normal   
controls
Mean 380.9 573.9
SD 96.0 142.8
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n 26 19
notes: The two-tailed P value is less than 0.0001; t = 5.4255; df = 43; 
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